Preimplantation Genetic Testing Market is Expected to Reach $1.2 Billion | MarketsandMarkets.

Chicago, Dec. 18, 2023 (GLOBE NEWSWIRE) — Preimplantation Genetic Testing market in terms of revenue was estimated to be worth $0.7 Billion in 2023 and is poised to reach $1.2 billion by 2028, growing at a CAGR of 11.4% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. The growth of this market is majorly driven by the increasing number of fertility clinics worldwide, and technological advancements in genetic analysis. However, the high procedural costs associated with preimplantation genetic testing may restrain the market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605

Preimplantation Genetic Testing Market Scope:

Report Coverage Details
Market Revenue in 2023 $0.7 Billion
Estimated Value by 2028 $1.2 Billion
Growth Rate Poised to grow at a CAGR of 11.4%
Market Size Available for 2021–2028
Forecast Period 2023–2028
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Procedure Type, Technology, Product, Application, Type of Cycle, and End User
Geographies Covered North America, Europe, Asia Pacific, and Rest of the World
Report Highlights Updated financial information / product portfolio of players
Key Market Opportunity Use of fertility treatment options by single parents and same-sex couples
Key Market Driver Declining fertility rate

Based on procedure type, the preimplantation genetic testing market is segmented into preimplantation genetic screening and preimplantation genetic diagnosis. The preimplantation genetic screening segment accounted for the largest share of the preimplantation genetic testing market. The large share of this segment can be attributed to factors such as greater awareness and acceptance of genetic screening techniques among prospective parents and increasing maternal age.

Based on technology, the preimplantation genetic testing market is segmented into PCR, NGS, FISH, CGH, and SNP segments. Next-generation sequencing segment is expected to dominate the preimplantation genetic testing market falling prices of sequencing, rapidly increasing penetration of NGS in diagnostics, and increasing use of these systems in fertility clinics and research institutes for preimplantation genetic diagnosis and preimplantation genetic screening.

On the basis of product and service, the preimplantation genetic diagnosis and screening market is segmented into instruments, reagents & consumables, and software & services. In 2022, the reagents and consumables segment dominated this market. The large share of this segment can be attributed to the increasing number of preimplantation genetic diagnoses and preimplantation genetic screening procedures performed worldwide.

On the basis of region, the global preimplantation genetic testing market is categorized into the North America, Europe, Asia-Pacific, and the RoW segments. North America holds the largest market share in 2022 due to the increasing government funding for genetic testing, and declining fertility rates. Other factors driving the demand for North America market include rising infertility among women in the US due to the growing prevalence of polycystic ovary syndrome (PCOS), the growing incidence of reproductive diseases such as chlamydia, and the increasing age of first-time pregnancy.

Buy a Preimplantation Genetic Testing Industry Report (245 Pages PDF with Insightful Charts, Tables, and Figures): https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=605

Preimplantation Genetic Testing market major players covered in the report, such as:

  • Illumina, Inc. (US)
  • Thermo Fisher Scientific Inc. (US)
  • Agilent Technologies, Inc. (US)
  • Revvity (US)
  • The Cooper Companies, Inc. (US)
  • Abbott (US)
  • Takara Bio Inc. (Japan)
  • Qiagen (Germany)
  • Vitrolife (Sweden)
  • Oxford Nanopore Technologies Plc (UK)
  • Oxford Gene Technology IP Limited (UK)
  • Yikon Genomics (China)
  • Shiva Scientific Company (India)
  • Nanjing Superyears Gene Technology Co. Ltd. (China)
  • Medicover Genetics (Germany)
  • Medgenome (India)
  • Fulgent Genetics (US)
  • Invicta Genetics (Poland)
  • Genea Limited (Australia)
  • Scigene Corporation (US)
  • Bioarray S.L. (Spain)
  • Unimed Biotech (Shanghai) Co. Ltd. (China)
  • Genemind Biosciences Co. Ltd. (China)
  • Berry Genomics (China)
  • Bangkok Genomics Innovation (Thailand)
  • and Among Others

Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=605

This research report categorizes the Preimplantation genetic testing market into the following segments and subsegments:

Regional Split

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Procedure Type Split

  • Preimplantation Genetic Screening
  • Preimplantation Genetic Diagnosis

Technology Split

  • Next-Generation Sequencing
  • Polymerase Chain Reaction
  • Fluorescence In Situ Hybridization
  • Comparative Genomic Hybridization
  • Single-Nucleotide Polymorphism

Product Split

  • Reagents and Consumables
  • Instruments
  • Software and Services

Application Split

  • Aneuploidy
  • Structural Chromosomal Abnormalities
  • Single Gene Disorders
  • X-Linked Disorders
  • HLA Typing
  • Gender Identification

Type of Cycle Split

  • Fresh Non-Donor
  • Frozen Non-Donor
  • Fresh Donor
  • Frozen Donor

End-user Split

  • Fertility Clinics
  • Hospitals
  • Diagnostic Laboratories
  • Other End Users

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=605

Preimplantation Genetic Testing Industry Recent Developments:

  • In 2023, Thermo Fisher Scientific Inc. (US) launched two new NGS-based test kits to support preimplantation genetic testing-aneuploidy (PGT-A), commonly used in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research.
  • In 2022, The Cooper Companies, Inc. (US) released the addition of Parental QC, Genetic PN check, and Origin of Aneuploidy to PGT-A testing as PGT-Complete.
  • In 2021, Vitrolife (Sweden) acquired Igenomix (Spain), a leader in reproductive genetic testing services primarily for IVF clinics.

Key Market Stakeholders:

  • Senior Management
  • End User
  • Finance/Procurement Department
  • R&D Department

Report Objectives:

  • To define, describe, segment, and forecast the global preimplantation genetic testing market by procedure type, technology, product, application, type of cycle, end user, and region.
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges).
  • To analyze the micro markets with respect to individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market.
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
  • To forecast the size of the market segments with respect to four regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World.
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies.
  • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence.

Related Reports:

Ultrasound Market

Digital PCR (dPCR) and Real-time PCR (qPCR) Market

Next Generation Sequencing (NGS) Market

In Vitro Fertilization Market

Infertility Treatment Market

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/preimplantation-genetic-testing-market.asp

Content Source: https://www.marketsandmarkets.com/PressReleases/preimplantation-genetic-testing.asp

CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Privacy & Cookies Policy